SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Recursion Pharmaceuticals is expected to provide updates regarding the clinical-stage pipeline programs on its second-quarter earnings call.

Investors weren't cheered by news from one of the biotech's rivals. Clinical-stage biotech Recursion Pharmaceuticals ' (RXRX -4.66%) stock took it on the chin in the first trading day of the week.

Clinical-stage biotech Recursion Pharmaceuticals ' (NASDAQ: RXRX) stock took it on the chin in the first trading day of the week. Monday saw investors back out of the company's shares, leaving ...

The latest JavaScript specification standardizes a well-balanced and thoughtful set of features, including the built-in global Iterator, new Set methods, improvements to regular expressions, and more.

Shares in biotech company Recursion Pharmaceuticals (RXRX -1.31%) surged by more than 12% by 11 a.m. ET today. The move is due to a de-risking event in its drug discovery pipeline.

Recursion Halts Four Pipeline Programs, Sharpening Cancer, Rare Disease Focus AI drug developer advances fourth Sanofi-partnered program, earns $7M milestone payment ...

AI specialist Recursion trims pipeline in latest shakeup The cuts, which involve three of Recursion’s most advanced drug programs, are expected to help extend the company’s cash runway into the middle ...

Recursion states that REC-1245 is the first program using the company’s end-to-end AI platform, spanning discovery, biology, chemistry, and the clinic. According to Chris Gibson, CEO of ...